Divi's Laboratories stock
Price history
+73.01% over the period1 year: from ₹6,462.50 (November 20, 2025) to ₹11,180.50 (November 20, 2026), +73.01%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | ₹11,180.50 |
| October 30, 2026 | ₹9,780.00 |
| September 30, 2026 | ₹9,291.50 |
| August 31, 2026 | ₹9,467.00 |
| July 31, 2026 | ₹8,056.00 |
| June 30, 2026 | ₹6,579.00 |
| May 29, 2026 | ₹6,667.00 |
| April 30, 2026 | ₹6,502.50 |
| March 30, 2026 | ₹5,947.00 |
| February 27, 2026 | ₹6,408.50 |
| January 30, 2026 | ₹6,051.00 |
| December 31, 2025 | ₹6,392.50 |
| November 28, 2025 | ₹6,477.00 |
| November 20, 2025 | ₹6,462.50 |
At a glance
The company
Manufacture and sale of generic active pharmaceutical ingredients, intermediates, nutraceuticals and carotenoids for pharmaceutical, food and beverage industries
Latest results
Quarter to September 30, 2026 · EPS ₹42.49 (estimate ₹32.10)
Next event
TickerLandia's take on Divi's Laboratories
- Pricier than usual relative to earnings: P/E on the latest fiscal year 116 vs a median of 40 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 88 vs 41 (+114%) in a group of 11.
- Strong point: Market momentum (97/100 in its group). Weak point: Dividend (34/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−5.44% from the 52-week high
Analysts · 28 analysts
Average target₹11,163.39−0.15% vs. price
Buy 18 · Hold 5 · Sell 5 · Buy
TickerLandia Fingerprint: Divi's Laboratories
Compared with similar companies: very strong momentum, very high price, and very high financial strength.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricevery high95
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 88.2 90 EV/EBITDA 63.3 99 Forward P/E 63.3 93 Price/book 16.5 96 Price/sales 24.3 96 Profitabilityhigh78
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 34.0% 88 ROA 12.9% 91 Gross margin 63.4% 42 ROE 20.1% 81 Net margin 27.6% 86 Earnings stabilityaverage41
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 6.4% 20 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh78
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +10.78% 64 Revenue growth (year over year) +35.40% 85 Earnings growth (year over year) +63.60% 84 Financial strengthvery high83
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.04 66 Interest coverage 129.5 81 Debt/equitycounts in reverse: lower means more financial strength 0.00 99 Current ratio 4.60 86 Dividendlow34
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 24 years 64 Dividend yield 0.3% 15 Payout ratio 23.7% 24 Market momentumvery strong97
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +73.01% 94 Distance from 200-day average +45.21% 99 Riskvery low18
How much the price swings.
Metric Value Position in group Volatility (60 days) 30.3% 33 Maximum drawdown (12 months) 12.4% 2
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Divi's Laboratories is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2026), Divi's Laboratories's P/E today is 115.6, above the median of its last 10 fiscal years (40.3; between 15.6 and 70.0 from 2017 to 2026). Divi's Laboratories's P/E (trailing 12 months): 88.2, +114% against the median of a group of 11 similar companies (41.2).
Compared with 11 similar companies
| Metric | Divi's Laboratories | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 88.2 | High | |
| Forward P/E | 63.3 | High | |
| Operating margin | 34.0% | High | |
| ROE | 20.1% | High | |
| Debt/equity | 0.00 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Divi's Laboratories. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
₹36.76B
Latest quarter · Q3 2026
Net income
₹11.27B
Latest quarter · Q3 2026
Quarterly net margin
30.7%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ₹2.97T
- P/E
- 88.2
- EPS
- ₹126.72
- Volume
- 404.83K
- Daily trading
- €86.81M
- Dividend yield
- 0.27%
- Last ex-dividend on July 24, 2026
How Divi's Laboratories is changing
All resultsRevenue grew 8.7% a year on average over the last 5 years
Operating margin rose from 26.1% to 28.2%
Less cash than profit: free cash flow equal to 11% of net income
Returns
Divi's Laboratories returns with dividends
₹1,000 invested in Divi's Laboratories 5 years ago, on November 22, 2021, would be worth ₹2,463 today with dividends reinvested: +146.30% in total, +19.78% per year. On price alone it would be ₹2,389 (+138.94%).
| Period | Divi's Laboratories | ₹1,000 becomes |
|---|---|---|
| 1 month | +21.66% | ₹1,217 |
| 6 months | +62.20% | ₹1,622 |
| Year to date | +74.90% | ₹1,749 |
| 1 year | +73.72% | ₹1,737 |
| 3 years | +208.89% | ₹3,089 |
| 5 years | +146.30% | ₹2,463 |
| 10 years | +926.42% | ₹10,264 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Divi's Laboratories: technical analysis
Divi's Laboratories is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.3% below its all-time closing high (₹11,565.50, November 9, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 68
- Between 30 and 70
- vs 200-session average
- +45.21%
Support and resistance
Price areas where Divi's Laboratories has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price₹11,180.50
- Support₹9,580.67−14.31%3 touches, last on October 7, 2026
- Support₹8,979.50−19.69%3 touches, last on October 14, 2026
- Support₹8,735.50−21.87%2 touches, last on October 23, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 30.3%
- Largest fall in the last year
- −12.37%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Divi's Laboratories: seasonality
Average monthly price change over 24 years
Over the last 24 years, the strongest month for Divi's Laboratories has been April: +7.50% on average, positive in 20 years out of 24. The weakest has been January: −5.61% on average, positive in 7 years out of 23. November, the current month, has been positive in 12 years out of 23 (+4.39% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −5.61% | −4.91% | 7 of 23 |
| February | −0.14% | −1.75% | 9 of 23 |
| March | +0.38% | +3.21% | 13 of 23 |
| April | +7.50% | +6.02% | 20 of 24 |
| May | +3.55% | +3.92% | 15 of 24 |
| June | +3.54% | +1.44% | 16 of 24 |
| July | +6.25% | +4.90% | 19 of 24 |
| August | +5.90% | +5.73% | 16 of 24 |
| September | +3.38% | +0.98% | 14 of 24 |
| October | +3.02% | +3.31% | 16 of 24 |
| November | +4.39% | +1.77% | 12 of 23 |
| December | +4.03% | +3.34% | 17 of 23 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Divi's Laboratories and its competitors
Clients in North America, Europe, Asia and India, along with other international buyers, make up the markets Divi's Laboratories serves. The company manufactures and sells generic active pharmaceutical ingredients, chemical intermediates and nutraceuticals, and it also provides custom synthesis and contract manufacturing for APIs and intermediates. Its carotenoid line includes astaxanthin, beta-carotene and lycopene, alongside vitamins supplied to producers of food, supplements and animal feed. It also exports its products.
- Headquarters
- Hyderabad, India
- Employees
- 11,565
- Founded
- 1990
- Chief executive
- Kiran Divi
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Divi's LaboratoriesDIVISLAB | $32.03B | 34.0% | 88.2 | +62.20% |
| Hansoh Pharmaceutical Group3692 | $23.77B | 37.3% | 25.0 | −8.51% |
| Jiangsu Hengrui Pharmaceuticals600276 | $46.71B | 27.4% | 35.1 | −7.75% |
| Sun Pharmaceutical IndustriesSUNPHARMA | $48.8B | 23.3% | 41.2 | +0.24% |
| Torrent PharmaceuticalsTORNTPHARM | $19.25B | 22.2% | 79.2 | +5.88% |
| Shionogi4507 | $16.75B | 31.6% | 11.2 | +2.83% |
Same industry or related industries, similar size. Compare Divi's Laboratories with its competitors · Full profile
